Which has better earnings and valuation, INDV or ALVO?

Indivior has higher revenue and earnings than Alvotech. Alvotech is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Indivior $1.24B 3.77 $210M $1.95 19.63 Alvotech $588.90M 2.01 $27.92M -$0.25 N/A

Is INDV or ALVO more profitable?

Indivior has a net margin of 19.44% compared to Alvotech's net margin of -14.36%. Alvotech's return on equity of -11.92% beat Indivior's return on equity. Company Net Margins Return on Equity Return on Assets Indivior 19.44% -219.26% 29.40% Alvotech -14.36% -11.92% -7.59%

Does the media refer more to INDV or ALVO?

In the previous week, Alvotech had 10 more articles in the media than Indivior. MarketBeat recorded 13 mentions for Alvotech and 3 mentions for Indivior. Alvotech's average media sentiment score of 0.63 beat Indivior's score of 0.32 indicating that Alvotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Indivior 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alvotech 5 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media favor ALVO or DNTH?

In the previous week, Alvotech had 7 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 13 mentions for Alvotech and 6 mentions for Dianthus Therapeutics. Alvotech's average media sentiment score of 0.63 beat Dianthus Therapeutics' score of 0.47 indicating that Alvotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alvotech 5 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Dianthus Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, ERAS or ALVO?

Alvotech has higher revenue and earnings than Erasca. Alvotech is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Erasca N/A N/A -$124.55M -$0.93 N/A Alvotech $588.90M 2.01 $27.92M -$0.25 N/A

Is ERAS or ALVO more profitable?

Erasca has a net margin of 0.00% compared to Alvotech's net margin of -14.36%. Alvotech's return on equity of -11.92% beat Erasca's return on equity. Company Net Margins Return on Equity Return on Assets Erasca N/A -35.31% -29.49% Alvotech -14.36% -11.92% -7.59%

Does the media refer more to ERAS or ALVO?

In the previous week, Erasca had 18 more articles in the media than Alvotech. MarketBeat recorded 31 mentions for Erasca and 13 mentions for Alvotech. Alvotech's average media sentiment score of 0.63 beat Erasca's score of -0.01 indicating that Alvotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Erasca 2 Very Positive mention(s) 0 Positive mention(s) 27 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Alvotech 5 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media refer more to ORKA or ALVO?

In the previous week, Alvotech had 5 more articles in the media than Oruka Therapeutics. MarketBeat recorded 13 mentions for Alvotech and 8 mentions for Oruka Therapeutics. Alvotech's average media sentiment score of 0.63 beat Oruka Therapeutics' score of -0.24 indicating that Alvotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oruka Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alvotech 5 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Alvotech (ALVO) Competitors

$3.93 +0.01 (+0.20%)

As of 09:55 AM Eastern

Compare

ALVO vs. INDV, DNTH, ERAS, ORKA, and KNSA

Should you buy Alvotech stock or one of its competitors? MarketBeat compares Alvotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Alvotech include Indivior (INDV), Dianthus Therapeutics (DNTH), Erasca (ERAS), Oruka Therapeutics (ORKA), and Kiniksa Pharmaceuticals International (KNSA). These companies are all part of the "pharmaceutical products" industry.

How does Alvotech compare to Indivior?

Indivior (NASDAQ:INDV) and Alvotech (NASDAQ:ALVO) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment.

Indivior presently has a consensus target price of $40.29, suggesting a potential upside of 5.24%. Alvotech has a consensus target price of $7.60, suggesting a potential upside of 93.88%. Given Alvotech's higher possible upside, analysts clearly believe Alvotech is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.00
Alvotech	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Indivior has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market. Comparatively, Alvotech has a beta of 0.21, meaning that its stock price is 79% less volatile than the broader market.

Indivior has higher revenue and earnings than Alvotech. Alvotech is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	$1.24B	3.77	$210M	$1.95	19.63
Alvotech	$588.90M	2.01	$27.92M	-$0.25	N/A

Indivior has a net margin of 19.44% compared to Alvotech's net margin of -14.36%. Alvotech's return on equity of -11.92% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indivior	19.44%	-219.26%	29.40%
Alvotech	-14.36%	-11.92%	-7.59%

In the previous week, Alvotech had 10 more articles in the media than Indivior. MarketBeat recorded 13 mentions for Alvotech and 3 mentions for Indivior. Alvotech's average media sentiment score of 0.63 beat Indivior's score of 0.32 indicating that Alvotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Indivior	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alvotech	5 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

60.3% of Indivior shares are held by institutional investors. 0.7% of Indivior shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Indivior beats Alvotech on 13 of the 17 factors compared between the two stocks.

How does Alvotech compare to Dianthus Therapeutics?

Alvotech (NASDAQ:ALVO) and Dianthus Therapeutics (NASDAQ:DNTH) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership.

Alvotech has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market. Comparatively, Dianthus Therapeutics has a beta of 1.18, indicating that its share price is 18% more volatile than the broader market.

Alvotech has a net margin of -14.36% compared to Dianthus Therapeutics' net margin of -12,998.50%. Alvotech's return on equity of -11.92% beat Dianthus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alvotech	-14.36%	-11.92%	-7.59%
Dianthus Therapeutics	-12,998.50%	-27.30%	-25.91%

In the previous week, Alvotech had 7 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 13 mentions for Alvotech and 6 mentions for Dianthus Therapeutics. Alvotech's average media sentiment score of 0.63 beat Dianthus Therapeutics' score of 0.47 indicating that Alvotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alvotech	5 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Dianthus Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alvotech has higher revenue and earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alvotech	$588.90M	2.01	$27.92M	-$0.25	N/A
Dianthus Therapeutics	$2.04M	2,210.65	-$162.34M	-$4.13	N/A

47.5% of Dianthus Therapeutics shares are owned by institutional investors. 3.0% of Dianthus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Alvotech currently has a consensus price target of $7.60, suggesting a potential upside of 93.88%. Dianthus Therapeutics has a consensus price target of $117.82, suggesting a potential upside of 42.83%. Given Alvotech's higher possible upside, equities analysts clearly believe Alvotech is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alvotech	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93

Summary

Alvotech beats Dianthus Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Alvotech compare to Erasca?

Erasca (NASDAQ:ERAS) and Alvotech (NASDAQ:ALVO) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.

Erasca has a beta of 0.73, meaning that its share price is 27% less volatile than the broader market. Comparatively, Alvotech has a beta of 0.21, meaning that its share price is 79% less volatile than the broader market.

67.8% of Erasca shares are held by institutional investors. 14.2% of Erasca shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Alvotech has higher revenue and earnings than Erasca. Alvotech is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Erasca	N/A	N/A	-$124.55M	-$0.93	N/A
Alvotech	$588.90M	2.01	$27.92M	-$0.25	N/A

Erasca presently has a consensus target price of $20.11, suggesting a potential upside of 47.12%. Alvotech has a consensus target price of $7.60, suggesting a potential upside of 93.88%. Given Alvotech's higher probable upside, analysts clearly believe Alvotech is more favorable than Erasca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Erasca	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Alvotech	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Erasca has a net margin of 0.00% compared to Alvotech's net margin of -14.36%. Alvotech's return on equity of -11.92% beat Erasca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Erasca	N/A	-35.31%	-29.49%
Alvotech	-14.36%	-11.92%	-7.59%

In the previous week, Erasca had 18 more articles in the media than Alvotech. MarketBeat recorded 31 mentions for Erasca and 13 mentions for Alvotech. Alvotech's average media sentiment score of 0.63 beat Erasca's score of -0.01 indicating that Alvotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Erasca	2 Very Positive mention(s)	0 Positive mention(s)	27 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Alvotech	5 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Erasca beats Alvotech on 8 of the 15 factors compared between the two stocks.

How does Alvotech compare to Oruka Therapeutics?

Oruka Therapeutics (NASDAQ:ORKA) and Alvotech (NASDAQ:ALVO) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, media sentiment, institutional ownership, analyst recommendations and profitability.

Oruka Therapeutics has a beta of -0.25, meaning that its stock price is 125% less volatile than the broader market. Comparatively, Alvotech has a beta of 0.21, meaning that its stock price is 79% less volatile than the broader market.

56.4% of Oruka Therapeutics shares are held by institutional investors. 23.5% of Oruka Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Oruka Therapeutics presently has a consensus price target of $131.30, suggesting a potential upside of 81.50%. Alvotech has a consensus price target of $7.60, suggesting a potential upside of 93.88%. Given Alvotech's higher possible upside, analysts plainly believe Alvotech is more favorable than Oruka Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Alvotech	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Oruka Therapeutics has a net margin of 0.00% compared to Alvotech's net margin of -14.36%. Alvotech's return on equity of -11.92% beat Oruka Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-26.16%	-25.00%
Alvotech	-14.36%	-11.92%	-7.59%

In the previous week, Alvotech had 5 more articles in the media than Oruka Therapeutics. MarketBeat recorded 13 mentions for Alvotech and 8 mentions for Oruka Therapeutics. Alvotech's average media sentiment score of 0.63 beat Oruka Therapeutics' score of -0.24 indicating that Alvotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oruka Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alvotech	5 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Alvotech has higher revenue and earnings than Oruka Therapeutics. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.94	N/A
Alvotech	$588.90M	2.01	$27.92M	-$0.25	N/A

Summary

Alvotech beats Oruka Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Alvotech compare to Kiniksa Pharmaceuticals International?

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Alvotech (NASDAQ:ALVO) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.

Kiniksa Pharmaceuticals International has a beta of 0.12, indicating that its share price is 88% less volatile than the broader market. Comparatively, Alvotech has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market.

In the previous week, Alvotech had 7 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 13 mentions for Alvotech and 6 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 1.14 beat Alvotech's score of 0.63 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kiniksa Pharmaceuticals International	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alvotech	5 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Kiniksa Pharmaceuticals International has a net margin of 9.69% compared to Alvotech's net margin of -14.36%. Kiniksa Pharmaceuticals International's return on equity of 13.26% beat Alvotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiniksa Pharmaceuticals International	9.69%	13.26%	9.86%
Alvotech	-14.36%	-11.92%	-7.59%

Kiniksa Pharmaceuticals International has higher revenue and earnings than Alvotech. Alvotech is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiniksa Pharmaceuticals International	$677.56M	6.26	$59.01M	$0.90	61.23
Alvotech	$588.90M	2.01	$27.92M	-$0.25	N/A

Kiniksa Pharmaceuticals International presently has a consensus price target of $60.86, suggesting a potential upside of 10.43%. Alvotech has a consensus price target of $7.60, suggesting a potential upside of 93.88%. Given Alvotech's higher possible upside, analysts plainly believe Alvotech is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiniksa Pharmaceuticals International	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	3.11
Alvotech	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Kiniksa Pharmaceuticals International beats Alvotech on 14 of the 17 factors compared between the two stocks.

Get Alvotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALVO vs. The Competition

Export

Metric	Alvotech	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.18B	$3.40B	$6.41B	$12.59B
Dividend Yield	N/A	2.32%	2.68%	5.81%
P/E Ratio	-15.68	19.90	24.59	24.44
Price / Sales	2.01	320.32	529.21	111.09
Price / Cash	17.99	56.54	27.92	37.84
Price / Book	-4.17	8.15	10.75	6.60
Net Income	$27.92M	$23.91M	$3.57B	$337.10M
7 Day Performance	-7.55%	2.18%	0.34%	-0.20%
1 Month Performance	17.37%	0.19%	-0.09%	1.68%
1 Year Performance	-58.07%	55.09%	29.31%	36.09%

Alvotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALVO Alvotech	3.7947 of 5 stars	$3.93 +0.2%	$7.60 +93.5%	-58.1%	$1.18B	$588.90M	N/A	1,460
INDV Indivior	2.522 of 5 stars	$38.14 -0.7%	$39.33 +3.1%	+173.2%	$4.65B	$1.24B	19.55	1,051
DNTH Dianthus Therapeutics	2.6302 of 5 stars	$79.78 -3.3%	$117.82 +47.7%	+389.6%	$4.36B	$2.04M	N/A	80	Gap Up
ERAS Erasca	2.2934 of 5 stars	$13.82 -4.2%	$20.11 +45.6%	+897.8%	$4.28B	N/A	N/A	120	Gap Up
ORKA Oruka Therapeutics	2.7723 of 5 stars	$68.37 -0.7%	$131.30 +92.0%	+519.3%	$4.12B	N/A	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALVO) was last updated on 6/22/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alvotech (ALVO) Competitors

ALVO vs. INDV, DNTH, ERAS, ORKA, and KNSA

How does Alvotech compare to Indivior?

Summary

How does Alvotech compare to Dianthus Therapeutics?

Summary

How does Alvotech compare to Erasca?

Summary

How does Alvotech compare to Oruka Therapeutics?

Summary

How does Alvotech compare to Kiniksa Pharmaceuticals International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALVO vs. The Competition

Alvotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alvotech (ALVO) Competitors

ALVO vs. INDV, DNTH, ERAS, ORKA, and KNSA

How does Alvotech compare to Indivior?

Do analysts rate INDV or ALVO?

Which has more risk and volatility, INDV or ALVO?

Which has better earnings and valuation, INDV or ALVO?

Is INDV or ALVO more profitable?

Does the media refer more to INDV or ALVO?

Do insiders and institutionals hold more shares of INDV or ALVO?

Summary

How does Alvotech compare to Dianthus Therapeutics?

Which has more volatility & risk, ALVO or DNTH?

Is ALVO or DNTH more profitable?

Does the media favor ALVO or DNTH?

Which has better valuation & earnings, ALVO or DNTH?

Do insiders & institutionals hold more shares of ALVO or DNTH?

Do analysts prefer ALVO or DNTH?

Summary

How does Alvotech compare to Erasca?

Which has more risk & volatility, ERAS or ALVO?

Do institutionals and insiders hold more shares of ERAS or ALVO?

Which has preferable earnings & valuation, ERAS or ALVO?

Do analysts recommend ERAS or ALVO?

Is ERAS or ALVO more profitable?

Does the media refer more to ERAS or ALVO?

Summary

How does Alvotech compare to Oruka Therapeutics?

Which has more risk and volatility, ORKA or ALVO?

Do institutionals & insiders hold more shares of ORKA or ALVO?

Do analysts recommend ORKA or ALVO?

Is ORKA or ALVO more profitable?

Does the media refer more to ORKA or ALVO?

Which has stronger valuation & earnings, ORKA or ALVO?

Summary

How does Alvotech compare to Kiniksa Pharmaceuticals International?

Which has more volatility & risk, KNSA or ALVO?

Does the media refer more to KNSA or ALVO?

Is KNSA or ALVO more profitable?

Which has better earnings & valuation, KNSA or ALVO?

Do analysts rate KNSA or ALVO?

Do institutionals and insiders hold more shares of KNSA or ALVO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALVO vs. The Competition

Alvotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools